Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2009

View Archived Issues

GeoVax presents update on clinical trials of its HIV/AIDS vaccine

Sanofi submits supplemental application to FDA for A(H1N1) pandemic vaccine

Clinical Data collaborates with CombinatoRx for novel B-cell cancer therapy

Terminal complement inhibitor eculizumab reduces clinical thrombosis in PNH patients

AZD-0530 fails to meet primary endpoint in phase II trial in extensive-stage SCLC

ADH-1 shows potent antitumor activity in vitro and in vivo in combination with erlotinib

ABT-869 combined with carboplatin/paclitaxel shown to be safe in NSCLC

Histamine H1 antagonist bilastine is safe in healthy human volunteers

CB1R antagonist AM-6545 improves plasma lipid profile and glucose tolerance in obese mice

Saphris approved by FDA for schizophrenia and bipolar I disorder

FDA approves Embeda for moderate to severe chronic pain

Abbott expands Xience V trial into crossover dual antiplatelet therapy trial

AGI and Axcan terminate AGI-010 agreement

FDA approves Pharming's IND for Prodarsan in Cockayne syndrome

NCI reports antiproliferative effect for cancer drug GAP-107B8

Pacgen acquires Xphase Pharmaceuticals

Patients enrolled in phase II Oncophage cancer vaccine trial in glioma

OncoGenex expands clinical development of OGX-427 in bladder cancer

Allergan claims sphingosine 1-phosphate receptor ligands as analgesics

Novel gamma-secretase modulators in early development at EnVivo Pharmaceuticals

First launch for Onglyza in U.S.

Endacea describes adenosine A1 antagonists as diagnostic agents

Merck Sharpe & Dohme and Merck & Co. report PARP inhibitors for cancer treatment

Panacos synthesizes new series of anti-HIV agents

Merck & Co. reports discovery of Cav2.2 calcium channel blocker with in vivo analgesic activity

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...